Microsure
About
About Microsure
Microsure develops MUSA-3 for open microsurgery and supermicrosurgery on very small lymphatic ducts, blood vessels and nerves. The system consists of a surgeon console and a cart carrying two robotic arms. A surgeon works from a digital or hybrid microscope and controls the arms with joysticks; motion scaling and tremor filtering translate those inputs into smaller, steadier instrument movements.
MUSA-3 accepts a surgeon's familiar microsurgical instruments through disposable adapters and is designed to reach angulated wound planes without requiring the operator to stabilise their hands on an external surface. Its workflow covers free-flap reconstruction, lymphatic surgery and peripheral-nerve procedures. The earlier MUSA-2 entered clinical studies and is no longer produced. MUSA-3 received a European CE mark in May 2026, allowing Microsure to move from development into clinical adoption and evidence generation while it continues work toward the United States market.
Funding
Investors
- Brabantse Ontwikkelings Maatschappij - Participant - Unknown - 1 funding event - first seen 2023-10-04
- Eindhoven University of Technology - Participant - Unknown - 1 funding event - first seen 2023-10-04
- European Innovation Council Fund - Participant - Government / Public - 1 funding event - first seen 2023-10-04
- Innovation Industries - Participant - Angel / Individual - 1 funding event - first seen 2023-10-04
- Invest-NL - Participant - Unknown - 1 funding event - first seen 2023-10-04
- Kineo - Participant - Unknown - 1 funding event - first seen 2023-10-04
- kineo finance - Participant - Angel / Individual - 1 funding event - first seen 2023-10-04
- Private investor groups - Participant - Unknown - 1 funding event - first seen 2023-10-04
- RvO - Participant - Unknown - 1 funding event - first seen 2023-10-04
- TCIM - Participant - Unknown - 1 funding event - first seen 2023-10-04
- Venturing Tech - Participant - Angel / Individual - 1 funding event - first seen 2023-10-04
Team
- Alex Joseph - Chief Executive Officer - Current operating leader for Microsure's robot-assisted microsurgery system as it transitions from development into clinical adoption.
Timeline
Events
- 2026-05-07 - Executive Hire - Microsure appoints Alex Joseph as CEO for clinical growth phase
Microsure appointed Alex Joseph as Chief Executive Officer, succeeding Iwan van Vijfeijken. The company framed the leadership transition around its move into clinical execution after MUSA-3 received CE mark approval. Joseph has been involved in MUSA-3 development and brings surgical robotics, clinical-environment, and regulated medical-device experience.
Source - 2026-05-07 - Regulatory - Microsure receives CE mark approval for MUSA-3 microsurgery robot
Microsure received CE mark approval for MUSA-3, enabling clinical use of the microsurgical robot in Europe. The approval moves MUSA-3 from product development into a clinical medical-device phase focused on evidence generation and adoption. Microsure said the next phase will focus on clinical evidence at leading European centres and partnerships for supermicrosurgical procedures.
Source - 2023-10-04 - Funding - Microsure raises €38 million Series B2 to advance MUSA-3 microsurgical robot
Microsure closed a €38 million Series B2 financing round to advance development of its MUSA-3 microsurgical robot. The company said the funding would support final development, clinical studies, FDA clearance work in the United States, and CE mark preparation in Europe. Investors included the European Innovation Council Fund, kineo finance, Invest-NL, Innovation Industries, Brabantse Ontwikkelings Maatschappij, TCIM, Eindhoven University of Technology, and Venturing Tech.
Source